Applied Immune Sciences Inc. on Thursday said it has filed forits second trip into the public markets, a 2 million-shareoffering of common stock.
The Menlo Park, Calif., company, which is developingtechnology for treatment of immune system disorders outsideof the body, in May completed a 2.6 million-share IPO at $12.On Thursday, the stock (NASDAQ:AISX) closed at $27.50, up $4.
During the first quarter, AIS expects to complete Phase I trialsof its CELLector technology for AIDS, in which a patient's T cellsare activated with lymphokines, multiplied and reinfused intothe body. Trial of the technology in kidney cancer, usingCELLector to harvest tumor-infiltrating lymphocytes, isexpected to start in the first half of the year, said CraigHuffaker, chief financial officer.
If the offering is completed, the company would have 9.2million shares outstanding. Underwriters MontgomerySecurities and Furman Selz Inc. have a 300,000-shareoverallotment option. -- DF
(c) 1997 American Health Consultants. All rights reserved.